OPEN ACCESS Freely available online

Translational Medicine

ISSN: 2161-1025

Opinion Article

# Pharmacogenomics as a Regenerative Medicine in Healthcare System

**Edward George***

*Department of Internal Medicine, University of London, Guildford Road, Chertsey, London, UK*

## DESCRIPTION

Pharmacogenomics is a field that combines pharmacology and genomics to study how an individual's genetic makeup affects their response to drugs. This relatively new field of study aims to personalize medication therapy and optimize drug efficacy while minimizing adverse reactions. With the advancement in technology, pharmacogenomics has become a promising tool to achieve the goal of personalized medicine. Pharmacogenomics analyzes how an individual's genetic variations affect the drug's absorption, metabolism, distribution, and excretion. These genetic variations are commonly known as Single Nucleotide Polymorphisms (SNPs). Pharmacogenomic testing can help identify the genetic variations responsible for the patient's drug response and help tailor the medication to their genetic profile. The benefits of pharmacogenomics are evident in various medical fields, including oncology, cardiology, psychiatry, and infectious disease. For example, patients with certain genetic variations are more prone to experience toxicity with chemotherapy drugs. Therefore, by identifying these patients, clinicians can tailor the chemotherapy regimen and avoid toxicity while maintaining the drug's efficacy. Similarly, genetic variations in patients with cardiovascular disease can affect their response to antiplatelet therapy, which can lead to a reduction in adverse cardiovascular events. Pharmacogenomics can also help in psychiatric disorders. For instance, patients with genetic variations in the *CYP2D6* gene are poor metabolizers of antidepressants, leading to a higher risk of adverse effects. Identifying these patients early can help the clinician select alternative therapies that are better suited to their genetic makeup, leading to improved patient outcomes.

Pharmacogenomics testing has also become important in the field of infectious diseases. Genetic variations in the *CYP2C19* gene affect the metabolism of the antiviral drug clopidogrel, which is commonly used to treat hepatitis C. Identifying these variations can help clinicians adjust the dose of the drug to ensure optimal treatment. In addition to improving patient outcomes, pharmacogenomics can also reduce healthcare costs.

Adverse Drug Reactions (ADRs) are a significant cause of morbidity and mortality worldwide and are estimated to cost billions of dollars each year. By using pharmacogenomic testing to predict the likelihood of ADRs, clinicians can avoid prescribing medications that are likely to cause adverse effects, thus reducing healthcare costs. However, there are some challenges to the widespread implementation of pharmacogenomics. One of the significant challenges is the cost of testing. Currently, pharmacogenomic testing is relatively expensive and may not be covered by insurance companies. Therefore, it may not be accessible to all patients, especially those with limited financial resources. Another challenge is the lack of standardization in pharmacogenomics testing, which can lead to inconsistent results across laboratories. This inconsistency can lead to confusion among clinicians and may hinder the widespread adoption of pharmacogenomics. Despite these challenges, pharmacogenomics holds immense promise in the field of personalized medicine. As more research is conducted, the cost of testing is likely to decrease, and the standardization of testing protocols is likely to improve, making it more accessible to patients. Furthermore, as more clinicians become familiar with pharmacogenomics, they will likely become more comfortable integrating it into their clinical practice.

## CONCLUSION

In conclusion, pharmacogenomics has the potential to revolutionize the field of medicine by providing personalized treatment based on an individual's genetic profile. The ability to tailor medication therapy to a patient's genetic makeup can improve patient outcomes, reduce adverse drug reactions, and ultimately reduce healthcare costs. Although there are challenges to the widespread implementation of pharmacogenomics, the benefits of this approach are undeniable. As the field continues to advance, we can expect to see more widespread adoption of pharmacogenomics, leading to improved patient outcomes and a more personalized approach to medicine.

**Correspondence to:** Edward George, Department of Internal Medicine, University of London, Guildford Road, Chertsey, London, UK, E-mail: edward@geogre.uk

**Received:** 27-Feb-2023, Manuscript No. TMCR-23-22834; **Editor assigned:** 01-Mar-2023, Pre QC No. TMCR-23-22834 (PQ); **Reviewed:** 15-Mar-2023, QC No. TMCR-23-22834; **Revised:** 22-Mar-2023, Manuscript No. TMCR-23-22834 (R); **Published:** 30-Mar-2023, DOI: 10.35248/ 2161-1025.23.13.284

**Citation:** George E (2023) Pharmacogenomics as a Regenerative Medicine in Healthcare System. Trans Med.13:284.